Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate

Anticancer Research

Volumn 19, Issue 1 A, 1999, Pages 189-195

  Chaplin, D J ^a   Pettit, G R ^b   Hill, S A ^c  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b ARIZONA STATE UNIVERSITY   (United States)

^c NONE

Author keywords

Cis Pt; Combretastatin a 4 phosphate; Radiation; Tumour blood vessels; Vascular targeting

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; COMBRETASTATIN A4; RUBIDIUM CHLORIDE RB 86;

ANIMAL TISSUE; ARTICLE; BLOOD FLOW; CELL LOSS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HISTOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MEDIATOR; MOUSE; NONHUMAN; PERFUSION; PRIORITY JOURNAL; RADIOTHERAPY; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CISPLATIN; FEMALE; MICE; MICE, INBRED CBA; NEOPLASMS, EXPERIMENTAL; REGIONAL BLOOD FLOW; STILBENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032950870     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Fan TP, Jaggar R and Bicknell R: Controlling the vasculature: angiogenesis,anti-angiogenesis and vascular targeting of gone therapy. Trends Pharmacol Sci 16 (2): 57-66, 1945.
2. Folkman J: Angiogenesis in cancer, vascular, rheumatoul and other disease. Nature Med 1: 27-31, 1995.
3. Folkman J: What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1991.
4. Denekamp J: Vascular endothelium as the vulnerable element in tumours. Acta Radiol. Oncol 23: 217-225, 1944.
5. Hill SA, Lonergan SJ, Denekamp J and Chaplin DJ: Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer 29: 1320-1324. (1993).
6. Hill SA, Williams KB and Denekamp J: Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action. Eur J Cancer Clin Oncol 25: 1419-1424, 1989.
7. Bibby MC, Double JA., Loadman PM and Duke CV: Reduction of tumour blood flow by flavone acetic acid: a possible component to therapy. J Natl Cancer Inst 81: 216-220, 1989.
8. Kallinowski F, Schaefer C, Tyler G and Vaupel P: In vivo targets of recombinant human tumour necrosis factor-α, blood flow, oxygen consumption and growth of isotransplanted rat tumours. Brit. J. Cancer, 60: 555-560, 1989.
9. Zwi LJ, Baguley BC, Gavin JB and Wilson WR: Blood flow failure as a major determinant in the anti-tumour action of flavone acetic acid. J Natl Cancer Inst 81: 1005-1013, 1989.
10. Ludford RJ: Colchicine in the experimental chemotherapy of cancer. J Natl Cancer Inst 6: 89-101, 1945.
11. Baguley BC, Holdaway KH, Thomsen LL, Zhuang L and Zwi LJ: Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine. Evidence for a vascular mechanism. Eur J Cancer 27: 482-487, 1991.
12. Atwell GR, Rewcastle GW, Baguley BC and Denny WA: Synthesis and antitumour activity of topologically related analogues of flavone acetic acid. Anticancer Drug Design 4: 161-169, 1989.
13. Rewcastle GW, Atwell GJ, Baguley BC, Boyd M, Thomsen LL, Zuang L and Denny WA: Potential anti-tumour agents. 63. Structure activity relationships for side-chain analogues of the colon 38 active-agent 9-oxo-9H-xanthene-4-acetic acid. J Med Chem 34: 2864-2870, 1991.
14. Laws AL, Matthew AM, Double JA and Bibby MC: Preclinical in vitro and in vivo activity of 5, 6-dimethylxanthenone-4-acetic acid. Brit J Cancer 71: 1204-1209, 1995.
15. Hill SA, Sampson LE and Chaplin DJ: Antivascular approaches to solid tumour therapy: Evaluation of vinblastine and flavone acetic acid. Int J Cancer 63: 119-123, 1995.
16. Chaplin DJ, Pettit GR, Parkins CS and Hill SA: Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Brit J Cancer 74: S86-S88, 1996).
17. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR and Chaplin DJ: Combretastatin A4. An agent that displays potent and selective toxicity towards tumour vasculature. Cancer Res 57: 1829-1834, 1997.
18. Sheldon PW and Hill SA: Hypoxic cell radiosensitisers and local control by X-ray of a transplanted tumour in mice. Brit J Cancer 35: 795-808, 1977.
19. Sapirstein LA: Regional blood flow by fractional distribution of indicators. Amer J Physiol 193: 161-168, 1958.
20. Hill SA and Denekamp J: Site dependent response of tumours to combined heat and radiation. Brit J Radiol 55: 905-913, 1982.
21. Smith KA, Hill SA, Begg AC and Denekamp J: Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Brit J Cancer 57: 247-253, 1988.
22. Chalkey HW: Method for the quantitative morphologic analysis of tissue. Int J Cancer Inst 4: 47-53, 1943.
23. Bcauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE and Brindlc KE: MRI and MRS of Combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Brit J Cancer 77: 1761-1767, 1998.
24. Male D: Cell migration and inflammation, Immunology. I Roitt J Brostoff and D Male London Moshy: 13.2-13.8, 1993.
25. Chaplin DJ: Keynote Address: Bioreductive therapy. Int J Radiat Oncol Biol Phys 22: 685-687, 1992.
26. Plowman J, Naraynan VL, Dykes D, Szarvasi E, Briet P, Yoder OC and Paull KD: Flavone acetic acid: a novel agent with preclinical antitumour activity against colon adenocarcinoma in mice. Cancer Treat Rep 70: 631-635, 1986.
27. Bibby MC, Phillips RM, Double JA and Pratesi G: Antitumour activity of flavone acetic acid (NS347512) in mice - influence of immune status. Brit J Cancer 63: 57-62, 1991.
28. Pratesi G, Roddfo M, Rovetta G and Parmiani G: Role of T-cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid. Eur J Cancer 10: 1079-1083, 1990.
29. Korbelik M, Krosl G, Krosl J and Dougherty GJ: The role of host lymphoid populations in the response of mouse EMT6 tumours to photodynamic therapy. Cancer Res 56: 5647-5652, 1996.
30. Somers SD and Adams DO: Enhancement of selective tumour cell binding by activated murine macrophages in response to phorhol myristatc acetate. J Immunol 136 (6): 2323-2332, 1986.
31. Perico N, Ostermann D, Bontempeill M, Morigi M, Amuchastegui CS, Zoja C, Akalin E. Sayegh MH and Remuzzi G: Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation. J Am Soc Nephrol 7 (4): 594-601, 1996.
32. Strom TB, Garovov MR, Carpenter DB and Merrill JP: Microtubule function in immune and nonimmune lymphocyte-mediated cytoxicity. Science 181(95): 171-173, 1973.